Cancer Immunotherapy
Interleukin 12 gene transfer retards fibrosarcoma growth and metastasis
Published in Gene Therapy Weekly, May 5th, 2005
"Cytokine-encoding viral vectors are considered to be promising in cancer gene immunotherapy. Interleukin 12 (IL-12) has been used widely for anti-tumor treatment, but the administration route and tumor characteristics strongly influence therapeutic efficiency. Meth-A fibrosarcoma has been demonstrated to be insensitive to IL-12 treatment via systemic administration," investigators in Japan report.
"In the present study, we developed an IL-12-encoding fiber-mutant adenoviral vector (AdRGD-IL-12) that showed enhanced gene transfection efficiency in Meth-A tumor cells, and the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-05-05)
More Articles from Gene Therapy Weekly
- Drug Development
ONYX-015 and MAP chemotherapy may help some patients with advanced sarcomas - Endocrinology
Limited diffusion impedes the transfection of pituitary tumors - Prostate Cancer
Radiotherapy and sKDR gene delivery demolish malignant prostate tumors - Virology
Pseudotyped lentiviral vector steers therapy to metastatic melanoma - Adverse Drug Reaction
Pre-existing immunity alters host response to systemic adenoviral vector - Allergy & Immunology
Inhaled antisense oligonucleotide alleviates murine asthma - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
